Literature DB >> 10534163

Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.

Z W Baloch1, S Abraham, S Roberts, V A LiVolsi.   

Abstract

The follicular variant of papillary carcinoma (FVPTC) is characterized by follicular growth pattern and tumor cells with appropriate nuclear features of papillary carcinoma. However, occasionally these lesions may show focal or multifocal instead of diffuse distribution of nuclear features of papillary carcinoma. Such lesions can be underdiagnosed as benign follicular nodule. Previous studies have shown that cytokeratins, especially 19, are helpful in differentiating papillary carcinoma from other benign and malignant follicular patterned lesions. In this study, we applied monoclonal antibodies to CK5/6/18, CK18, CK10/13, CK20, CK17, and CK19 to paraffin sections of formaldehyde-fixed tissue from 26 cases of FVPTC with multifocal distribution of papillary cancer nuclei, 10 cases of usual variant of papillary carcinoma, 1 case of Warthin's tumor-like papillary carcinoma, and 2 cases of the columnar cell carcinoma. CK19 stained strongly and diffusely all cases of papillary carcinoma. FVPTC cases showed strong staining of the areas with papillary cancer nuclei in all cases and moderate to strong staining in areas of tumor without obvious nuclear features of papillary cancer. Normal thyroid parenchyma adjacent to the tumor nodule showed focal staining in most cases; however, tissue away from the tumor nodule failed to show any staining. All cases of usual type of papillary carcinoma, 2 of columnar cell carcinoma, and 1 Warthin's tumor-like papillary carcinoma showed strong and diffuse staining with CK19 and failed to show any staining of adjacent normal thyroid parenchyma. Similar but less intense staining patterns were seen with CK17 and CK20. The control group, consisting of cases of follicular adenoma, follicular carcinoma, and hyperplastic nodule, showed no staining with CK19. We suggest that if one is using immunohistochemistry to aid in the diagnosis of cases of FVPTC with multifocal distribution of nuclear features of papillary cancer, an antibody panel comprising CKs 17, 19, and 20 may prove helpful. In addition, we hypothesize that the staining of adjacent nontumorous thyroid parenchyma with CK19, seen only in cases of FVPTC, suggests that some factors secreted/produced by this particular tumor may lead to modification in keratin expression of surrounding follicular epithelium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534163     DOI: 10.1016/s0046-8177(99)90033-3

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

Review 1.  Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate.

Authors:  R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Authors:  Jennifer L Hunt; Zubair W Baloch; Leon Barnes; Patricia A Swalsky; Cindy L Trusky; E Sesatomi; Sydney Finkelstein; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 3.  Best practice in thyroid pathology.

Authors:  C E Anderson; K M McLaren
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

4.  The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease.

Authors:  Suna Erkiliç; N Emrah Koçer
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

5.  Can misdiagnosis in pre-operative FNAC of thyroid nodule influence surgical treatment?

Authors:  P Del Rio; R Minelli; S Cataldo; G Ceresini; G Robuschi; L Corcione; A Guazzi; R Nizzoli; M Sianesi
Journal:  J Endocrinol Invest       Date:  2010-06-28       Impact factor: 4.256

6.  Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.

Authors:  Yoon-La Choi; Mi Kyung Kim; Jin-Won Suh; Joungho Han; Jung Han Kim; Jung Hyun Yang; Seok Jin Nam
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

7.  RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation.

Authors:  Eunah Shin; Woung Youn Chung; Woo Ick Yang; Cheong Soo Park; Soon Won Hong
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

8.  Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.

Authors:  Suna Erkiliç; Abdullah Aydin; N Emrah Koçer
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.

Authors:  Lei Gong; Ping Chen; Xianjun Liu; Ying Han; Yanping Zhou; Weidong Zhang; Hong Li; Chuanjia Li; Jiang Xie
Journal:  Gland Surg       Date:  2012-05

10.  Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis.

Authors:  Shuai Dong; Xiao-Jun Xie; Qing Xia; Yi-Jun Wu
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.